Is this you? Create Your Porfile
Avatar

Douglas Alan Lorenz

Pfizer

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Douglas Alan Lorenz is active.

Explore More

Publication

Featured researches published by Douglas Alan Lorenz.

Archive | 2000

Pharmaceutical compositions providing enhanced drug concentrations

William John Curatolo; Ravi Mysore Shanker; Walter Christian Babcock; Dwayne Thomas Friesen; James Alan Schriver Nightingale; Douglas Alan Lorenz

Archive | 2001

Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors

William John Curatolo; Dwayne Thomas Friesen; Michael Jon Gumkowski; Douglas Alan Lorenz; James Alan Schriver Nightingale; Roger Benjamin Ruggeri; Ravi Mysore Shanker

Archive | 2002

Pharmaceutical compositions of dispersions of drugs and neutral polymers

Dwayne Thomas Friesen; Michael Jon Gumkowski; Rodney James Ketner; Douglas Alan Lorenz; James Alan Schriver Nightingale; Ravi Mysore Shanker; James Blair West

Archive | 2003

Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor

Dwayne Thomas Friesen; David Keith Lyon; Douglas Alan Lorenz; Bruno C. Hancock; Timothy Joseph Pfizer Global R. D. Mcdermott; Ravi Mysore Shanker

Archive | 2001

Pharmaceutical compositions of glycogen phosphorylase inhibitors

Dennis J. Hoover; Ravi Mysore Shanker; Dwayne Thomas Friesen; Douglas Alan Lorenz; James Alan Schriver Nightingale

Archive | 2006

Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea

Tracy Lee Boyden; Susan Deborah La Greca; Feng Guo; Douglas Alan Lorenz; Ravi Mysore Shanker; Franzanne Vreeland

Archive | 2003

Pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors

William John Curatolo; Michael Jon Gumkowski; Roger Benjamin Ruggeri; Ravi Mysore Shanker; Marshall David Crew; Dwayne Thomas Friesen; Douglas Alan Lorenz; James Alan Schriver Nightingale; Daniel Todd Smithey; Warren Kenyon Miller

Archive | 2006

Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor

Dwayne Thomas Friesen; Douglas Alan Lorenz; Scott Wendell Smith

Archive | 2007

Solid dispersion comprising a poorly water soluble drug

Rodney James Ketner; Douglas Alan Lorenz; David Keith Lyon

Archive | 2004

Compositions comprising an HIV protease inhibitor

Scott Wendell Smith; Dwayne Thomas Friesen; Douglas Alan Lorenz; David Keith Lyon; Rodney James Ketner; James Blair West

Explore More

Collaboration

Dive into the Douglas Alan Lorenz's collaboration.

Top Co-Authors
Avatar

Ravi Mysore Shanker

Pfizer

View shared research outputs
Top Co-Authors
Avatar

Dwayne Thomas Friesen

Pfizer

View shared research outputs
Top Co-Authors
Avatar

James Alan Schriver Nightingale

Novartis

View shared research outputs
Top Co-Authors
Avatar

Rodney James Ketner

Pfizer

View shared research outputs
Top Co-Authors
Avatar

William John Curatolo

Pfizer

View shared research outputs
Top Co-Authors
Avatar

Michael Jon Gumkowski

Pfizer

View shared research outputs
Top Co-Authors
Avatar

David Keith Lyon

California Institute of Technology

View shared research outputs
Top Co-Authors
Avatar

Roger Benjamin Ruggeri

Pfizer

View shared research outputs
Top Co-Authors
Avatar

Bruno C. Hancock

Pfizer

View shared research outputs
Top Co-Authors
Avatar

Marshall David Crew

Pfizer

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge